Ironwood Pharma (IRWD) Misses Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. QGEN
9. SPCX
10. WDC

Go back to Ironwood Pharma (IRWD) Misses Q3 EPS by 5c

Ironwood Pharmaceuticals Provides Third Quarter 2015 Investor Update

November 3, 2015 4:05 PM EST

LINZESS® (linaclotide) prescriptions increased approximately 38% to over 550 thousand in third quarter 2015 compared to third quarter 2014

LINZESS U.S. net sales increased approximately 47% to $117.5 million in third quarter 2015 compared to third quarter 2014

Ironwood revenue increased approximately 134% to $39.6 million in third quarter 2015 compared to third quarter 2014

Multiple positive development milestones including linaclotide 72mcg Phase III data, initiation of Phase IIb linaclotide colonic release trial, and advancement of sGC platform

CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More